Hebei one nucleic acid testing agency was investigated; orthopedic spine nation -mining is about to open the bid; dental implants collection covers fixed -point private hospitals

At 2:30 pm on September 21, the National High -value Consumption Lianqi Office held a training session of the national organizational orthopedic spine consumables. Gao Xue, the leader of Liancai's Ji Cai, chaired the meeting.

According to the latest notice, the third round of consumables of the orthopedic spine market will be opened on September 27th.

The core content of the corporate training meeting is to guide the enterprise reasonable quotation. The meeting explained 10 key contents such as procurement products, procurement demand, the highest and effective declaration price, application requirements, declaration quotation, determination of product selection, agreement procurement, procurement execution, time arrangement, material requirements, etc., and summarized the previous summary Corporate questions are answered.

According to the Liancai Office documents, the spine consumables are divided into 14 of the cervical spine front road plate fixed fusion system, the cervical rear road nail rod fixed system, the cervical spine front road plate fixed fusion system, and the cervical spine front road plate fixed fusion system Product system. Each system consists of two parts: main components and optional components. The company needs to report the prices of the main components and the corresponding service price. Optional components do not need to be quoted.

"Taking the fixed system fixation system of the cervical spine, the main components include rods, screws, screws, and horizontal connections. Optional components include pillow bone plates, pillow bone clamps, pillow bone nails, pillow bone sticks, hooks, etc. In the end, the amount is not very large, and it will be handed over to various places or some alliances in the future. "

In terms of the selection rules, companies within each bidding unit conduct bidding in accordance with the auction product system, and produce the proposed enterprises through price competition. Unlike the coronary stent and artificial joints, the concentrated band procurement cycle of orthopedic spine consumables is 3 years. The actual implementation date of the selection results of the alliance is calculated. The results of the selection will be announced on September 27.

The training meeting also reminded that on September 27th, 7:30 to 9:30, the application materials were submitted by the receiving enterprise on the spot. In principle, each declaration of one representative is selected, and no more than two representatives should be submitted to the application materials to submit the application materials to the application materials, and they will leave. Enterprises can sign up for the nearby meeting with the Provincial Medical Insurance Bureau of the Provincial Medical Insurance Bureau where the registered location or the province where the headquarters are located, and witness the bid opening process online.

What other "weapons" are worthy of attention this week? New policy insights in the industry, new corporate movements to observation, market investment and financing review, "Medical Economic News" follow -up report!

01

New policy insights in the industry

1

The dental implants are collected! Purchasing scope covers fixed -point private hospitals

On September 22, the Sichuan Provincial Medical Insurance Bureau officially issued the "Announcement on the Procurement of the Concentration of Oral implant System Upgrade Alliance (No. 1)" (hereinafter referred to as "Document No. 1"), which comprehensively launched the provincial inter -alliance concentration belt of the oral implant system Overseas procurement work.

The "Announcement of No. 1" released this time focuses on the range of varieties, corporate qualifications, participation entities, procurement cycles, procurement rules, and subsequent related work arrangements for planting systems.

The concentrated purchase of the oral implant system for the purchase product is composed of the implant, repairing the base platform, and the accessories package. According to the plant material, it is divided into a fourth -level pure titanium implant product system and titanium alloy planting. There are two product system categories in the body product system.

In terms of collecting and mining scope, it is clear that public medical institutions that carry out oral dental implants in 31 provinces across the country shall participate. The designated private medical institutions of medical insurance will participate in accordance with the requirements of the designated agreement management, encourage other medical institutions to participate, and enhance the "group purchase of group purchases in quantitative price exchange. "Ability; expanded to 3 years at the procurement cycle, and clarified the number of renewal procurement agreements in the next year in principle not lower than the agreed purchase volume of the previous year, stabilizing the industry's expectations and ensuring stability of supply.

Next, the Sichuan Provincial Medical Insurance Bureau will organize reports, bid opening and other tasks in an orderly manner in accordance with the contents of the "Announcement of No. 1" to ensure that the people enjoy the reform dividends of the planting system as soon as possible.

2

Hunan: Strictly regulate the use and charge of "surgical robot"

On September 23, the Hunan Provincial Medical Insurance Bureau issued the "Notice on Regulating the use and charging behavior of standardized operating robot auxiliary operating systems".

It is understood that this is the first provincial -level document issued by medical service charges and medical insurance payment policies, which are the first related to regulate surgical robot auxiliary operating systems, covering many sectors.

The "Notice" states that medical institutions use "surgical robots" to assist orthopedics, head and neck surgery, thoracic surgery, cardiac surgery, general surgery, urological surgery, vascular surgery, gynecological surgery operation, and uniformly use the "addition" as the "addition" of surgical prices to charge In accordance with the benchmark price of the surgical items, a certain proportion is added. Other consumables consumed during the use of surgical robots. According to the actual function of the "surgical robot", classification and collection are implemented.

It is worth noting that the increase in fees for surgical robot auxiliary operating systems will not be incorporated into the scope of the payment of the medical insurance fund, and the procedures are adjusted according to factors such as medical service project guarantee demand, fund revenue and expenditure conditions, and bearing capacity.

02

New movement of enterprises

1

Shijiazhuang Hehe Medical Inspection Laboratory detected that the mixed pipe was positive and did not report.

On September 24th, according to the report of the Shijiazhuang Public Security Bureau, given the recent continuous epidemic situation in Yuhua District and the source is unknown, the Shijiazhuang Municipal Health and Health Commission, the Municipal Public Security Bureau and other departments have mixed up related professional experts to inspect the city's nucleic acid testing agencies. During the inspection, it was found that the "Shijiazhuang Hehe Medicine Inspection Lab" on September 14 was not reported to the one -tube 20: 1 mixed pipe positive sample of the Nucleic acid 361 community in Yuhua District. Community communication appeared on the 21st. The laboratory was suspected of illegal crimes, and the Shijiazhuang police had filed a case for investigation. Data from Tianyan Check shows that Shijiazhuang Hehe Medical Inspection Laboratory Co., Ltd. was established in November 2021. It has a registered capital of 20 million yuan, with a real -capital of 5.82 million yuan, and the number of participants is 0. The company's major shareholders and actual controllers are Beijing Hehe Medical Diagnosis Technology Co., Ltd., which was established in 2010. It has paid 78.89 million yuan in actual capital and 173 participants.

2

Libang Instrument New Biochemical Analyzer I20 is expected to be listed in China in the first half of next year

On September 21, Libang Instrument released a record of investor relations. The company was investigated by 27 institutional units on September 20, 2022. Libang Instrument said that the company's second quarter performance achieved growth in the third quarter. The listing of new products (rehabilitation products for pots) has brought incremental increase and consumables for blood gas analyzers. Regarding whether it can continue to grow rapidly in the third and fourth quarters, the company stated that there will be certain challenges.

Libang Instrument has launched a new generation of blood gas biochemical analyzer i20 based on the photochemical platform this year. It is expected to be listed in the overseas market this year in Q4. It is expected to be listed in the first half of 2023. Wet blood gas analyzer. In addition, the company is actively deploying portable households.

3

Zhijiang Biological "fully automatic nucleic acid extraction and detection and analysis system" obtains medical device registration certificate

On September 20, Zhijiang Biological Announcement, the company's product fully automatic nucleic acid extraction and detection and analysis system has recently obtained a national three -type medical device registration certificate. The scope of application is the purification and PCR detection analysis of fully automated sample nucleic acid extraction and PCR detection. This product is fully closed for negative pressure automation operations. It uses UV+HEPA dual system to prevent cross -pollution. It covers an area of ​​less than 0.4 square meters. It can efficiently solve the needs of rapid detection of nucleic acids. It is suitable for various laboratories, as well as mobile car and other space environments such as relatively limited relative space environment. The place.

4

Beautiful Mosos coating coronary arterial balloon expansion catheter was approved for listing

Lan Fan Medical announced on the evening of September 20 that the company's subsidiary Shandong Jiwei Medical Products Co., Ltd. developed and produced an innovative medical device product "Beautiful Momo Painting Coronary Arterial Poin Pipe Expansion Pipe" was recently obtained by the State Drug Administration (NMPA ) Approval registration.

Beautiful Mosos coating coronary arterial balloon expansion catheter consists of the ducting catheter and the drug coating on the balloon, and the balloon catheter is composed of ball pockets, remote pipes, transition pipes, and proximal pipes. This product adheres to the surface of the balloon through the polyethylene oxide carrier. wall.

As a drug release technology in the vascular balloon, drugs can release drugs with effective treatment concentrations on the lesion, solve and treat coronary heart disease intervention and stenosis in the bracket. This product is suitable for the treatment of vascular diameter 2.0mm-2.75mm primary coronary arterial vascular lesions, which provides new choices for patients with primary small vascular lesions.

03

Market investment financing review

1

Tencent plans to subscribe for 291 million yuan to subscribe to Yuyue Medical subsidiary Xunjie Medical New Registered Capital

On September 19, Yuyue Medical issued an announcement saying that the company's wholly -owned subsidiary Xun Jie Medical intends to introduce strategic investors in the form of capital increase and shareholding, Shenzhen Social Chuangxiang Shan Technology Co., Ltd. The latter, the latter subscribed for 291 million yuan in cash to subscribe for the new registered capital of Xunjie Medical, of which 36.3354 million yuan was included in the Capita Medical Registered Capital, and 254 million yuan was included in the Capita Medical Capital Capital. The company gave up the capital increase Priority subscription rights. After the capital increase was completed, Xunjie Medical Registration Capital increased from 150 million yuan to 186 million yuan.

According to the information of the Tianyan Eyes, Shenzhen Social Chuangxiangshan Technology Co., Ltd. was established by Shenzhen Tencent Computer System Co., Ltd. 99.9%. After the capital increase was completed, Tencent will become the second largest shareholder of Xunjie Medical.

2

Jianshi Technology's prospectus, introducing Xianjian Technology as the cornerstone investor

Jianshi Technology officed from September 23 to September 29, 2022. It plans to offer 8.0764 million H shares worldwide, of which about 10%of Hong Kong offices, about 90%of international offering, and 15%of excess equity; The sale price per share is HK $ 26.70-28.80, and 200 shares per hand. It is expected that H shares will start buying and selling on the Stock Exchange at 9 am on October 10, 2022 (Monday).

Jianshi Technology has entered into a cornerstone investment agreement with Xianjian Technology Company. Cornerstone investors have agreed to subscribe for the number of sale shares purchased at a total amount of $ 20 million.

Jianshi creatures are mainly engaged in the development of innovation of minimally invasive intervention therapy of heart valve. A series of treatment solutions for different types of structural heart disease (including triral valve disease, aortic valve disease, two -pointed disease, and heart failure)Program.3

The first domestic, super -display micro, high -precision surgical robot platform received several hundred million A round financing

On September 21, Ang Tai Micro Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Ang Tai Microex") announced the completion of hundreds of millions of yuan A financing.This round of financing is led by Qiming Investment, which is adjacent to Xingde Venture Capital, Dongjiu Xinyi Capital, Lingang Blue Bay Fund, and Ruihua Holdings.

According to Angtai Microex Press, it is a robot company that has successfully achieved the whole process without shake operations.The success of this financing not only provided great thrust for the future development of Ang Tai Micro, but also injected vitality into the surgical robot industry and minimally invasive surgery.

Edit: Liu Xiaomei

- END -